文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

ESC 工作组关于心脏细胞生物学:心血管研究的立场文件:组织工程策略与细胞疗法相结合,用于治疗缺血性心脏病和心力衰竭中的心脏修复。

ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure.

机构信息

Institute of Cardiology and Center of Excellence on Aging, "G. d'Annunzio" University-Chieti, Italy.

University of Texas Medical School in Houston, USA.

出版信息

Cardiovasc Res. 2019 Mar 1;115(3):488-500. doi: 10.1093/cvr/cvz010.


DOI:10.1093/cvr/cvz010
PMID:30657875
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6383054/
Abstract

Morbidity and mortality from ischaemic heart disease (IHD) and heart failure (HF) remain significant in Europe and are increasing worldwide. Patients with IHD or HF might benefit from novel therapeutic strategies, such as cell-based therapies. We recently discussed the therapeutic potential of cell-based therapies and provided recommendations on how to improve the therapeutic translation of these novel strategies for effective cardiac regeneration and repair. Despite major advances in optimizing these strategies with respect to cell source and delivery method, the clinical outcome of cell-based therapy remains unsatisfactory. Major obstacles are the low engraftment and survival rate of transplanted cells in the harmful microenvironment of the host tissue, and the paucity or even lack of endogenous cells with repair capacity. Therefore, new ways of delivering cells and their derivatives are required in order to empower cell-based cardiac repair and regeneration in patients with IHD or HF. Strategies using tissue engineering (TE) combine cells with matrix materials to enhance cell retention or cell delivery in the transplanted area, and have recently received much attention for this purpose. Here, we summarize knowledge on novel approaches emerging from the TE scenario. In particular, we will discuss how combinations of cell/bio-materials (e.g. hydrogels, cell sheets, prefabricated matrices, microspheres, and injectable matrices) combinations might enhance cell retention or cell delivery in the transplantation areas, thereby increase the success rate of cell therapies for IHD and HF. We will not focus on the use of classical engineering approaches, employing fully synthetic materials, because of their unsatisfactory material properties which render them not clinically applicable. The overall aim of this Position Paper from the ESC Working Group Cellular Biology of the Heart is to provide recommendations on how to proceed in research with these novel TE strategies combined with cell-based therapies to boost cardiac repair in the clinical settings of IHD and HF.

摘要

缺血性心脏病(IHD)和心力衰竭(HF)的发病率和死亡率在欧洲仍然很高,在全球范围内呈上升趋势。IHD 或 HF 患者可能受益于新型治疗策略,例如细胞疗法。我们最近讨论了细胞疗法的治疗潜力,并就如何改善这些新型策略的治疗转化提出了建议,以实现有效的心脏再生和修复。尽管在优化细胞来源和递送方法方面取得了重大进展,但细胞疗法的临床疗效仍不尽如人意。主要障碍是移植细胞在宿主组织有害微环境中的低植入率和存活率,以及内源性具有修复能力的细胞数量少甚至缺乏。因此,需要新的方法来输送细胞及其衍生物,以实现 IHD 或 HF 患者的基于细胞的心脏修复和再生。利用组织工程(TE)的策略将细胞与基质材料结合起来,以增强移植区域内细胞的保留或细胞递送,最近为此目的受到了广泛关注。在这里,我们总结了来自 TE 方案的新兴新方法的知识。特别是,我们将讨论细胞/生物材料(例如水凝胶、细胞片、预制基质、微球和可注射基质)组合如何增强移植区域内的细胞保留或细胞递送,从而提高 IHD 和 HF 细胞疗法的成功率。我们不会专注于使用具有完全合成材料的经典工程方法,因为它们的材料性能不理想,不适合临床应用。ESC 工作组心脏细胞生物学的这份立场文件的总体目标是就如何在这些新型 TE 策略与基于细胞的疗法相结合的研究中提供建议,以促进 IHD 和 HF 的临床环境中的心脏修复。

相似文献

[1]
ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure.

Cardiovasc Res. 2019-3-1

[2]
Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.

Eur Heart J. 2016-6-14

[3]
Recent advancements in tissue engineering for stem cell-based cardiac therapies.

Ther Deliv. 2013-4

[4]
Cellular Therapy for Ischemic Heart Disease: An Update.

Adv Exp Med Biol. 2019

[5]
Cellular cardiomyoplasty and cardiac tissue engineering for myocardial therapy.

Adv Drug Deliv Rev. 2010-3-6

[6]
Application of injectable hydrogels for cardiac stem cell therapy and tissue engineering.

Rev Cardiovasc Med. 2019-12-30

[7]
Cell therapy, 3D culture systems and tissue engineering for cardiac regeneration.

Adv Drug Deliv Rev. 2013-12-27

[8]
Myocardial regeneration: Roles of stem cells and hydrogels.

Adv Drug Deliv Rev. 2011-3-1

[9]
Cardiac Cell Therapy for Heart Repair: Should the Cells Be Left Out?

Cells. 2021-3-13

[10]
Material-based engineering strategies for cardiac regeneration.

Curr Pharm Des. 2014

引用本文的文献

[1]
Mitigating murine acute and chronic Coxsackievirus B3-induced myocarditis with human right atrial appendage-derived stromal cells.

Stem Cells Transl Med. 2025-3-18

[2]
Human Cardiac Microtissues Display Improved Engraftment and Survival in a Porcine Model of Myocardial Infarction.

J Cardiovasc Transl Res. 2025-3-13

[3]
Current Advances and Future Directions of Pluripotent Stem Cells-Derived Engineered Heart Tissue for Treatment of Cardiovascular Diseases.

Cells. 2024-12-18

[4]
Revolutionizing medicine: recent developments and future prospects in stem-cell therapy.

Int J Surg. 2024-12-1

[5]
Past Trends and Future Directions of Cardiac Regenerative Medicine - A Systematic Analysis of Clinical Trial Registries.

J Cardiovasc Transl Res. 2025-2

[6]
Monascus pigment-protected bone marrow-derived stem cells for heart failure treatment.

Bioact Mater. 2024-9-4

[7]
Review on Emerging Therapeutic Strategies for Managing Cardiovascular Disease.

Curr Cardiol Rev. 2024

[8]
A versatile high-throughput assay based on 3D ring-shaped cardiac tissues generated from human induced pluripotent stem cell-derived cardiomyocytes.

Elife. 2024-4-5

[9]
Inducing positive inotropy in human iPSC-derived cardiac muscle by gene editing-based activation of the cardiac α-myosin heavy chain.

Sci Rep. 2024-2-16

[10]
Regenerative Medicine and Nanotechnology Approaches against Cardiovascular Diseases: Recent Advances and Future Prospective.

Curr Stem Cell Res Ther. 2025

本文引用的文献

[1]
Inhibiting Inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ Transplant Acceptance.

Immunity. 2018-11-6

[2]
A Bioprinted Cardiac Patch Composed of Cardiac-Specific Extracellular Matrix and Progenitor Cells for Heart Repair.

Adv Healthc Mater. 2018-10-31

[3]
3D bioprinting for cardiovascular regeneration and pharmacology.

Adv Drug Deliv Rev. 2018-7-24

[4]
4D Biofabrication: Materials, Methods, and Applications.

Adv Healthc Mater. 2018-7-5

[5]
Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates.

Nat Biotechnol. 2018-7-2

[6]
Deep phenotyping of human induced pluripotent stem cell-derived atrial and ventricular cardiomyocytes.

JCI Insight. 2018-6-21

[7]
'Reprogrammed' stem cells approved to mend human hearts for the first time.

Nature. 2018-5

[8]
Cell therapy trials for heart regeneration - lessons learned and future directions.

Nat Rev Cardiol. 2018-11

[9]
Cardiac Remodeling: Endothelial Cells Have More to Say Than Just NO.

Front Physiol. 2018-4-11

[10]
Stem Cells in Osteochondral Tissue Engineering.

Adv Exp Med Biol. 2018

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索